Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,819 | $5 | $11 | $5 |
| G&A Expenses | $6,261 | $8 | $11 | $7 |
| SG&A Expenses | $6,261 | $8 | $11 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $0 | $0 |
| Operating Expenses | $12,080 | $16 | $22 | $12 |
| Operating Income | -$12,080 | -$16 | -$22 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $13 | $1 | $0 | -$0 |
| Pre-Tax Income | -$12,067 | -$15 | -$22 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,067 | -$15 | -$21 | -$12 |
| % Margin | – | – | – | – |
| EPS | -2,836.41 | -12.97 | -18.32 | -10.37 |
| % Growth | -21,769% | 29.2% | -76.7% | – |
| EPS Diluted | -2,836.41 | -12.97 | -18.32 | -10.37 |
| Weighted Avg Shares Out | 4 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 4 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$104 | $0 | $0 | $0 |
| Depreciation & Amortization | $91 | $1 | $18 | $12 |
| EBITDA | -$12,080 | -$15 | $0 | $0 |
| % Margin | – | – | – | – |